HilleVax (HLVX) Stock Price, News & Analysis

Company Overview

HilleVax, Inc. is a clinical-stage biotechnology company focused on the development of broadly protective vaccines against enteric pathogens. The company leverages a proprietary O-antigen platform to generate multivalent vaccine candidates designed to elicit immunity to multiple strains of enterotoxigenic Escherichia coli (ETEC), Shigella and Vibrio cholerae. HilleVax’s lead candidate, HIL-214, is currently advancing through Phase I clinical trials to assess safety and immunogenicity in adult populations.

Founded as a spin-out from Hilleman Laboratories with support from philanthropic and industry partners, HilleVax has built a pipeline of product candidates aimed at addressing diseases that disproportionately impact low- and middle-income countries as well as travelers. In addition to HIL-214, the company is developing second-generation candidates for shigellosis and cholera, each leveraging the same O-antigen conjugation technology to streamline manufacturing and broaden strain coverage. Strategic collaborations and research partnerships underpin the company’s efforts to optimize vaccine formulations and accelerate global development.

Headquartered in Cambridge, Massachusetts, HilleVax conducts research and development activities in the United States while engaging with international public health agencies, academic institutions and non-governmental organizations to support clinical trial execution and eventual vaccine deployment. Led by CEO William J. Harty, the management team brings extensive experience in vaccine development, regulatory affairs and global commercialization planning. As a publicly listed entity on NASDAQ under the symbol HLVX, HilleVax is positioning itself to address unmet medical needs in enteric disease prevention on a global scale.

Key Stats

• Today's Range: $2.09 to $2.09
• 50-Day Range: $2.06 to $2.12
• 52-Week Range: $1.77 to $2.17
• Volume: N/A
• Average Volume: 532,880 shs
• Market Capitalization: $104.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Company Calendar

• Last Earnings: 8/06/2025
• Today: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HLVX
• CIK: 1888012
• Web: www.hillevax.com
• Phone: 617-213-5054
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$147.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -34.29%
• Return on Assets: -28.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.39
• Quick Ratio: 26.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.10 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 50,140,000
• Free Float: 37,656,000
• Market Cap: $104.79 million
• Optionable: Not Optionable
• Beta: 0.77